Peptron Eyes Differentiation As Exenatide Progresses For Parkinson’s
With the recent completion of GMP manufacturing facilities and sizable funding, South Korean peptide therapeutics company Peptron is set to begin a Phase II clinical trial of sustained release exenatide for Parkinson’s, which if successful could pave the way to a first-in-class, disease-modifying treatment for the disease.
You may also be interested in...
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
Oncolytic virus firm SillaJen, which hoped to get back on track and resume stock trading after it found a new owner last year, is set to be delisted from Korea’s Kosdaq market as the exchange makes a preliminary decision.
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.